Does Medicare cover GLP-1s for weight loss? The new $50 Bridge, explained

For years, Medicare was barred by statute from paying for a drug used only to lose weight. That is why, even as GLP-1s became the most talked-about medications in the country, a Medicare beneficiary with obesity (and no diabetes) usually could not get Wegovy or Zepbound covered at all. On July 1, 2026, that changes, at least temporarily, through a new program CMS calls the Medicare GLP-1 Bridge.

What the Bridge is

The Bridge is a temporary, nationwide demonstration run by CMS. The shape of it:

• Dates: July 1, 2026 through December 31, 2027. (It was first set to end December 31, 2026, then extended a year.)
• Cost: a flat $50 per month copay for a covered GLP-1.
• Structure: it runs separately from regular Part D. Part D plans do not have to opt in for their eligible members to get access, and they do not carry the cost. In practice, that means access is automatic for beneficiaries who qualify, handled at the pharmacy once your prescriber’s paperwork is approved.

Which drugs are covered

The Bridge covers the GLP-1s that are FDA-approved specifically for weight reduction: all formulations of Wegovy (semaglutide), the KwikPen formulation of Zepbound (tirzepatide), and Foundayo. (See our plain-English Foundayo glossary entry if that name is new to you.)

Worth flagging: the diabetes versions of these molecules, Ozempic and Mounjaro, are not part of this program. Those have long been covered by Medicare when prescribed for type-2 diabetes, which is a separate pathway with its own rules.

Who qualifies

Two things have to be true:

1. You are enrolled in a Medicare Part D plan. The Bridge sits on top of Part D enrollment.
2. You meet CMS’s clinical criteria. Your prescriber submits a prior authorization attesting that you fall into one of the program’s categories, which are based on BMI and related clinical conditions. CMS sets the exact thresholds, so the CMS Bridge page is the place to confirm the current numbers rather than relying on a number you read in a news story.

The prior authorization is the step most people get tripped up on. If yours is denied, a denial is not the end of the road: our free prior-authorization and appeal-letter templates give you an evidence-based starting point to push back.

The catches the headlines skip

The “$50 a month” line is real, but read the fine print:

• The $50 does not count toward your deductible or your out-of-pocket cap. Per KFF, the copay does not apply to the Part D deductible or the out-of-pocket maximum ($2,100 in 2026, rising to $2,400 in 2027). So it sits outside your normal drug spending, it does not help you reach catastrophic coverage faster.
• Low-income subsidies do not apply. Beneficiaries in the Low-Income Subsidy (LIS) program still pay the $50; the usual LIS cost-sharing help is carved out of this program.
• It is temporary. Coverage ends December 31, 2027 unless something replaces it. If you start, plan for what happens when the Bridge closes, because stopping a GLP-1 typically means regaining much of the weight.
• Weight-loss drugs only. The Bridge is for the obesity indication. It does not change coverage for the diabetes versions.

Why it is only a stopgap: the BALANCE Model

The Bridge exists because the bigger plan did not happen on schedule. CMS had proposed a five-year demonstration for 2027 to 2031, the BALANCE Model, to build GLP-1 coverage into both Medicare Part D and Medicaid for the longer term.

The Medicare Part D half stalled. Per KFF, CMS announced it would not move forward with the BALANCE Model in Medicare for 2027, because major Part D plan sponsors were reluctant to participate as designed and an 80% participation threshold was not met. CMS has not announced a restart, so the permanent Medicare path is uncertain. The Bridge, extended through 2027, is the temporary answer while that gets sorted out.

What about Medicaid?

This is where it connects to coverage you may already have. The Medicaid side of the BALANCE Model is still moving forward: states can voluntarily join starting in 2026 (with a July 31, 2026 application deadline), using standardized coverage criteria that match the Medicare Bridge.

That sits on top of the patchwork that already exists, where whether your state’s Medicaid covers GLP-1s for weight loss varies a lot from state to state. We track that, state by state, with each state’s official drug-list link, on our GLP-1 coverage by state page.

What to do now

• On Medicare with obesity? Talk to your clinician about whether you meet the Bridge criteria and ask them to submit the prior authorization once it opens July 1. Confirm the specifics with your Part D plan, and keep our appeal templates handy in case of a denial.
• On Medicaid, or checking your state? See whether your state covers GLP-1s for weight loss and find its official drug list on the state coverage page.
• Not on either? Check whether you even meet the clinical criteria with our am I a candidate? tool, then compare every provider by real all-in cost.

None of this is medical or eligibility advice, and only Medicare, your plan, and your clinician can tell you what you qualify for. But for millions of older adults who were locked out of these drugs entirely, a $50 month is a genuinely new option, for the next year and a half.